About this trial
Somatic mutations in the MAP (mitogen-activated protein) kinase pathway have been found in about 80% of papillary thyroid tumors (PTCs). The evaluation of the PTC mutational profile is crucial for the definition of the prognosis and for predicting the effects of targeted and personalized therapies. Molecular characterization by mass spectrometry (Mass ARRAY) allows the search for multiple mutations in a single experiment, in a sensitive, fast and economic way. A Mass ARRAY platform (PTC-MA) was developed, capable of identifying the presence of the most common somatic point mutations and rearrangements in PTC (Pesenti et al., Endocrine 2017). The aim of the study is to characterize the mutational profile of a large series of papillary thyroid carcinomas (PTC). Tumor samples will be analyzed using our PTC-MA platform. The molecular profile of PTCs will be correlated with the clinical and prognostic characteristics of the patients.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
patients with papillary thyroid cancer
patients whose tumor tissue can be recovered for genetic analysis
Disqualifiers
patients who did not give consent
patients lost to follow-up
tumor samples not suitable for genetic analysis
Trial population
Patients diagnosed with papillary thyroid cancer, operated and followed by our Center of Excellence for the Diagnosis and Treatment of Thyroid Tumors
Trial design
Cohort
Prospective
Treatments tested in this trial
Genotyping
GeneticCharacterization of genetic profile of tumor tissues
Treatment groups
Trial outcomes
Primary outcomes
Mutational profile of PTCs
The mutational profile of about 600 PTCs will be characterized and correlate with the clinical characteristics and patient outcomes
Sponsors and contacts
Click on the lead sponsor to view all of their trials.